New treatment aims to hold back silent blood cancer before it strikes
NCT ID NCT04776395
Summary
This study is testing whether a new immunotherapy drug called iberdomide, given alone or with a steroid (dexamethasone), can delay or prevent a silent, early-stage blood cancer from progressing to active, symptomatic multiple myeloma. It will enroll 68 adults with intermediate or high-risk smoldering myeloma who are not yet showing symptoms. The main goal is to see how well the treatment works and how safe it is for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.